Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-01-11, Stock:NVS, The news for the past five days is as follows:
2018-01-04: NEWS1: How Is Novo Nordisk’s New Generation Insulin Segment Positioned after 3Q17?.NEWS2: Enough With the Excuses! Tesla Needs a New Magic Trick.NEWS3: Why Juno Therapeutics Stock Cooled Off in December.NEWS4: Why Juno Therapeutics Stock Cooled Off in December.NEWS5: Enough With the Excuses! Tesla Needs a New Magic Trick.NEWS6: Novartis Gets Second Breakthrough Designation for Kisqali.NEWS7: Novartis Gets Second Breakthrough Designation for Kisqali.NEWS8: The Swiss Stock Market Climbed Past 9,500 Points.NEWS9: Novartis: Promacta Gets FDA Breakthrough Therapy Designation For SAA.
2018-01-05: NEWS1: 4 Biotech Stocks to Watch in the New Year.NEWS2: Why Momenta Pharmaceuticals Rallied 15.6% Today.NEWS3: Why Momenta Pharmaceuticals Rallied 15.6% Today.NEWS4: Cancer Space Update: New Regulatory Status for 3 Major Drugs.NEWS5: Cancer Space Update: New Regulatory Status for 3 Major Drugs.NEWS6: The Swiss Stock Market Reached A New All-Time High.
2018-01-08: NEWS1: Amgen's (AMGN) Xgeva Gets FDA Approval for Multiple Myeloma.NEWS2: Health Care Sector Update for 01/08/2018: PODD,NTEC,NVS,CELG.NEWS3: Here's Why Momenta Pharmaceuticals, Inc. Reversed Course Today.NEWS4: Health Care Sector Update for 01/08/2018: MDRX,NTEC,NVS,CELG.NEWS5: Foreign Stock Roundup: Nintendo's Switch Surpasses Wii Record Sales, Petrobras to Settle Investor Lawsuit for $2.95B.NEWS6: Alzheimer's takes Another Hit as Pfizer Ends Research in this Area.NEWS7: 3 Soaring Gene-Editing Biotech Stocks: Which Is the Best Buy?.NEWS8: How Did Novo Nordisk’s NovoMix and Human Insulin Perform in 2017?.NEWS9: The Swiss Stock Market Eased Back From All-Time Highs.
2018-01-09: NEWS1: Ignyta’s Drug Pipeline.NEWS2: A Close Look at Ignyta’s Licensing Agreement.NEWS3: AbbVie Expects Peak Sales of $7 Billion for Imbruvica.NEWS4: Assessing Incyte’s 3Q17 Product Portfolio.NEWS5: Analyst Recommendations for Ignyta and Its Peers in January 2018.NEWS6: How Was Incyte’s Revenue Stream in 3Q17?.NEWS7: 5 Companies Hit 52-Week Highs.NEWS8: Why AbbVie Is Focused on Expanding Risankizumab’s Label for Multiple Immunology Indications.NEWS9: Valeant on the Street: Analyst Recommendations in December 2017.NEWS10: FDA Approvals Surge in 2017: Here's a Look at the Numbers.NEWS11: The Swiss Stock Market Broke Out To A New All-Time High.NEWS12: Novartis Announces Initiation Of SURPASS, Head-to-head Trial Of Cosentyx.
2018-01-10: NEWS1: Perjeta Could Significantly Boost Roche’s Revenue Growth in 2018.NEWS2: Novartis becomes latest big-name collaborator for Chapel Hill company.NEWS3: Merck's Keytruda Combo Gets Breakthrough Therapy Status.NEWS4: Novartis Starts Trial on Psoriasis Drug Cosentyx Biosoimilar.NEWS5: Ignyta and Its Key Risks in 2018.NEWS6: Why AbbVie Wants Imbruvica to Be a Foundation Therapy in Hematologic Oncology.NEWS7: Inside Ignyta’s Financial Performance.NEWS8: The Swiss Stock Market Pulled Back From Yesterday's New High.

Answer: Decrease